During the last session, Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s traded shares were 1.7 million, with the beta value of the company hitting 2.00. At the end of the trading day, the stock’s price was $2.69, reflecting an intraday loss of -7.24% or -$0.21. The company’s market capitalization is $715.86M, and the average intraday trading volume over the past 10 days was 1.49 million shares, and the average trade volume was 1.57 million shares over the past three months.
Autolus Therapeutics plc ADR (AUTL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AUTL has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
Autolus Therapeutics plc ADR (AUTL) registered a -7.24% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -7.24% in intraday trading to $2.69, hitting a weekly high. The stock’s 5-day price performance is -7.88%, and it has moved by -19.22% in 30 days. Based on these gigs, the overall price performance for the year is -40.22%. The short interest in Autolus Therapeutics plc ADR (NASDAQ:AUTL) is 6.29 million shares and it means that shorts have 2.48 day(s) to cover.
The consensus price target of analysts on Wall Street is $7.6, which implies an increase of 64.61% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7.6 and $7.6 respectively. As a result, AUTL is trading at a discount of -182.53% off the target high and -182.53% off the low.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
Statistics show that Autolus Therapeutics plc ADR has outperformed its competitors in share price, compared to the industry in which it operates. Autolus Therapeutics plc ADR (AUTL) shares have gone down -40.62% during the last six months, with a year-to-date growth rate more than the industry average at 21.67% against 17.10. In the rating firms’ projections, revenue will increase 920.38% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.98M as predicted by 6 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 17.52M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 3.32%. While earnings are projected to return 24.87% in 2024.
AUTL Dividends
Autolus Therapeutics plc ADR is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 20.49 million shares, is of BLACKSTONE INC.’s that is approximately 9.2207% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $71.29 million.
